Click on each title to read more!
20 June 2022
Waves of COVID-19 in the past year have brought to the attention of the scientific community the different variants of COVID-19. Whether it is the current (at the time of writing) Omicron variant or some other future variant, there are questions on how these different strains affect COVID-19 immunity in...
17 June 2022
Dr. Charles Strom, MD PhD was recently featured in the Bloomberg Master’s of Business Podcast. This podcast overviews Dr. Strom’s career in medical testing and gives insight into the past, present, and future landscape of medicine in the United States. Featured in the podcast is Dr. Stroms’ work at Liquid...
07 February 2022
In view of the global COVID-19 pandemic, the EFIRM technology has been on the cutting edge of helping work towards the resolution of the crisis. Read about a recent application of the EFIRM technology for mRNA COVID-19 vaccinations in saliva in the respected Journal of Immunology: Journal of Immunology from...
03 July 2021
MDPI cancers has recently published an exciting paper regarding liquid biopsy and its potential applications in therapeutic treatment monitoring. A cohort of 22 lung cancer subjects with samples taken periodically over a period of 61 to 272 days was evaluated with EFIRM, NGS, and ddPCR. This publication was a project...
24 July 2020
Three exciting new papers have been published on the EFIRM technology, continuing to show EFIRM’s immense viability as a tool for liquid biopsy of cancer. EFIRM for Monitoring of Lung Cancer Mutations In a work spearheaded by Dr. Ning Li[1] in collaboration with the NIH/National Cancer Institute, EFIRM was used...
23 January 2020
EZLife has recently had its work in mitochondrial DNA profiling in meat samples published in the Analytical Chimica Acta. As opposed to traditional technologies that require the meat to be homogenized, DNA extracted, and run on qPCR, the EFIRM technique is extremely simple, requiring only a simple immersion in an...
10 April 2019
April 10th, 2019 - EZLife Bio and UCLA recently completed a major milestone in the advancement of EFIRM liquid biopsy, completing initial CLIA-LDT qualification tests in collaboration with the Molecular Diagnostics Laboratory at the UCLA School of Medicine. This completion is a major milestone, demonstrating that EFIRM is a highly...
20 November 2018
EZLife Bio’s recent research initiative with the UCLA School of Dentistry was recently featured on genomeweb. Read about how our new initiative with the UCLA School of Dentistry and UCLA School of Medicine can help transform lung cancer screening.
13 November 2018
EZLife Bio recently wrapped up its trade shows for the year. We covered a lot of different tradeshows. Here are some fun highlights from all our recent trade shows. EZLife Bio’s Founder and CEO, Dr. Wei Liao, explaining the EFIRM platform and technology to customers at the 256th National Meeting...
15 October 2018
EZLife Bio, in collaboration with the UCLA School of Dentistry recently published a groundbreaking study on using EFIRM for detection of early stage plasma samples. Using a clinical cohort from National Cheng Kung University Hospital (成大醫院)，EFIRM was able to achieve unprecedenented sensitivity and specificity on detecting EGFR mutations in a...
01 October 2018
NIH-NCI has recently awarded 5 million to UCLA in order to study EFIRM early stage lung cancer screening! This news was featured on the UCLA Newsroom This U01 is an academic industrial partnership between UCLA and EZLife Bio. EZLife Bio will provide critical support on all instrumentation development and automation...